AR032449A1 - Un procedimiento para producir la forma i cristalina de cabergolina, es decir, 1((6-alilergolin-8beta-il)-carbonil)-1-(3-dimetilaminopropil)-3-etilurea, forma v de solvato de cabergolina, y un procedimiento para producir la forma v de solvato de cabergolina - Google Patents
Un procedimiento para producir la forma i cristalina de cabergolina, es decir, 1((6-alilergolin-8beta-il)-carbonil)-1-(3-dimetilaminopropil)-3-etilurea, forma v de solvato de cabergolina, y un procedimiento para producir la forma v de solvato de cabergolinaInfo
- Publication number
- AR032449A1 AR032449A1 ARP010101263A ARP010101263A AR032449A1 AR 032449 A1 AR032449 A1 AR 032449A1 AR P010101263 A ARP010101263 A AR P010101263A AR P010101263 A ARP010101263 A AR P010101263A AR 032449 A1 AR032449 A1 AR 032449A1
- Authority
- AR
- Argentina
- Prior art keywords
- cabergoline
- cabergolina
- solvato
- procedure
- produce
- Prior art date
Links
- KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 title abstract 10
- 229960004596 cabergoline Drugs 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 abstract 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 abstract 3
- 208000001089 Multiple system atrophy Diseases 0.000 abstract 2
- 208000018737 Parkinson disease Diseases 0.000 abstract 2
- 102000003946 Prolactin Human genes 0.000 abstract 2
- 108010057464 Prolactin Proteins 0.000 abstract 2
- 208000005793 Restless legs syndrome Diseases 0.000 abstract 2
- 229940097325 prolactin Drugs 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 206010033799 Paralysis Diseases 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 239000013078 crystal Substances 0.000 abstract 1
- 238000002425 crystallisation Methods 0.000 abstract 1
- 230000008025 crystallization Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000001035 drying Methods 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 230000000750 progressive effect Effects 0.000 abstract 1
- 238000011084 recovery Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
- C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
- C07D457/06—Lysergic acid amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
- C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0007308.0A GB0007308D0 (en) | 2000-03-24 | 2000-03-24 | Process for preparing crystalline form | of cabergoline |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR032449A1 true AR032449A1 (es) | 2003-11-12 |
Family
ID=9888433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010101263A AR032449A1 (es) | 2000-03-24 | 2001-03-19 | Un procedimiento para producir la forma i cristalina de cabergolina, es decir, 1((6-alilergolin-8beta-il)-carbonil)-1-(3-dimetilaminopropil)-3-etilurea, forma v de solvato de cabergolina, y un procedimiento para producir la forma v de solvato de cabergolina |
Country Status (31)
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0007308D0 (en) | 2000-03-24 | 2000-05-17 | Pharmacia & Upjohn Spa | Process for preparing crystalline form | of cabergoline |
| GB0007307D0 (en) * | 2000-03-24 | 2000-05-17 | Pharmacia & Upjohn Spa | Crystalline form || of cabergoline |
| DE10043321B4 (de) * | 2000-08-24 | 2005-07-28 | Neurobiotec Gmbh | Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung |
| DE10053397A1 (de) * | 2000-10-20 | 2002-05-02 | Schering Ag | Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen |
| DE10064453A1 (de) * | 2000-12-16 | 2002-07-04 | Schering Ag | Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen |
| RS81804A (sr) * | 2002-03-15 | 2006-10-27 | Pharmacia Corporation | Postupak za dobijanje kristalnog oblika kabergolina |
| WO2003078392A2 (en) * | 2002-03-15 | 2003-09-25 | Pharmacia Corporation | Process for preparing crystalline form i of cabergoline |
| IL155545A (en) | 2003-04-21 | 2009-12-24 | Finetech Pharmaceutical Ltd | Solvate form of cabergoline |
| AU2004238833A1 (en) * | 2003-05-08 | 2004-11-25 | Ivax Pharmaceuticals S.R.O. | Polymorphs of cabergoline |
| GB0409785D0 (en) * | 2004-04-30 | 2004-06-09 | Resolution Chemicals Ltd | Preparation of cabergoline |
| GB0505965D0 (en) | 2005-03-23 | 2005-04-27 | Resolution Chemicals Ltd | Preparation of cabergoline |
| GB0515430D0 (en) * | 2005-07-27 | 2005-08-31 | Resolution Chemicals Ltd | Preparation of cabergoline |
| US7339060B2 (en) | 2005-03-23 | 2008-03-04 | Resolution Chemicals, Ltd. | Preparation of cabergoline |
| EP1925616A1 (en) * | 2006-10-26 | 2008-05-28 | LEK Pharmaceuticals D.D. | Process for the preparation of crystal forms of cabergoline via stable solvates of cabergoline |
| EP1953157A1 (en) | 2007-01-31 | 2008-08-06 | LEK Pharmaceuticals D.D. | New crystal form of cabergoline |
| US8637099B2 (en) * | 2007-08-29 | 2014-01-28 | Max Zeller Sohne Ag | Use of Vitex agnus castus extracts for preparing a medicament |
| EP4074552B1 (en) * | 2021-04-16 | 2024-04-03 | Thermo King LLC | Electrical connection unit |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3019322A1 (de) | 1980-05-21 | 1981-12-03 | Merck Patent Gmbh, 6100 Darmstadt | Psychopharmakon sowie verwendung von adenosinderivaten |
| US4526892A (en) * | 1981-03-03 | 1985-07-02 | Farmitalia Carlo Erba, S.P.A. | Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas |
| GB2103603B (en) * | 1981-08-11 | 1985-04-11 | Erba Farmitalia | Ergoline derivatives |
| GB9205439D0 (en) * | 1992-03-12 | 1992-04-22 | Erba Carlo Spa | Process for the synthesis of ergoline derivatives |
| JPH08502759A (ja) | 1993-08-18 | 1996-03-26 | アルコン ラボラトリーズ,インコーポレイテッド | 緑内障治療用のエルゴリン誘導体の使用 |
| US20020010197A1 (en) | 1998-01-13 | 2002-01-24 | John Dixon | Pharmaceutical compositions comprising a compound having dopamine (d2) receptor agonist activity and a compound (b) having beta2-adrenoreceptor agonist activity |
| PL343593A1 (en) | 1998-03-27 | 2001-08-27 | Upjohn Co | Use of cabergoline in the treatment of restless legs syndrome |
| GB0007308D0 (en) | 2000-03-24 | 2000-05-17 | Pharmacia & Upjohn Spa | Process for preparing crystalline form | of cabergoline |
| GB0007309D0 (en) | 2000-03-24 | 2000-05-17 | Pharmacia & Upjohn Spa | Crystalline form V|| of cabergoline |
| GB0007307D0 (en) | 2000-03-24 | 2000-05-17 | Pharmacia & Upjohn Spa | Crystalline form || of cabergoline |
-
2000
- 2000-03-24 GB GBGB0007308.0A patent/GB0007308D0/en not_active Ceased
-
2001
- 2001-03-13 PE PE2001000237A patent/PE20011140A1/es not_active Application Discontinuation
- 2001-03-19 SI SI200130045T patent/SI1272489T1/xx unknown
- 2001-03-19 WO PCT/EP2001/003099 patent/WO2001070740A1/en not_active Ceased
- 2001-03-19 NZ NZ521316A patent/NZ521316A/en unknown
- 2001-03-19 EE EEP200200545A patent/EE05088B1/xx not_active IP Right Cessation
- 2001-03-19 HK HK03104554.7A patent/HK1052348B/zh not_active IP Right Cessation
- 2001-03-19 EA EA200201016A patent/EA005928B1/ru unknown
- 2001-03-19 IL IL15098501A patent/IL150985A0/xx active IP Right Grant
- 2001-03-19 JP JP2001568941A patent/JP4184666B2/ja not_active Expired - Fee Related
- 2001-03-19 AR ARP010101263A patent/AR032449A1/es unknown
- 2001-03-19 HU HU0300591A patent/HUP0300591A3/hu unknown
- 2001-03-19 CZ CZ20023176A patent/CZ20023176A3/cs unknown
- 2001-03-19 CN CNB018070051A patent/CN1188412C/zh not_active Expired - Fee Related
- 2001-03-19 ES ES01936098T patent/ES2208602T3/es not_active Expired - Lifetime
- 2001-03-19 AT AT01936098T patent/ATE250601T1/de not_active IP Right Cessation
- 2001-03-19 MX MXPA02009283A patent/MXPA02009283A/es active IP Right Grant
- 2001-03-19 US US10/239,636 patent/US6727363B2/en not_active Expired - Fee Related
- 2001-03-19 PT PT01936098T patent/PT1272489E/pt unknown
- 2001-03-19 EP EP01936098A patent/EP1272489B1/en not_active Expired - Lifetime
- 2001-03-19 KR KR1020027012590A patent/KR100827558B1/ko not_active Expired - Fee Related
- 2001-03-19 PL PL01358253A patent/PL358253A1/xx not_active Application Discontinuation
- 2001-03-19 CA CA002402836A patent/CA2402836A1/en not_active Withdrawn
- 2001-03-19 DK DK01936098T patent/DK1272489T3/da active
- 2001-03-19 AU AU62110/01A patent/AU780747B2/en not_active Ceased
- 2001-03-19 DE DE60100858T patent/DE60100858T2/de not_active Expired - Fee Related
- 2001-03-19 BR BR0109507-2A patent/BR0109507A/pt not_active Application Discontinuation
- 2001-03-19 SK SK1358-2002A patent/SK13582002A3/sk unknown
- 2001-03-22 MY MYPI20011364A patent/MY134189A/en unknown
-
2002
- 2002-07-29 ZA ZA200206045A patent/ZA200206045B/xx unknown
- 2002-07-30 IL IL150985A patent/IL150985A/en not_active IP Right Cessation
- 2002-09-10 NO NO20024321A patent/NO20024321L/no not_active Application Discontinuation
-
2003
- 2003-10-31 US US10/698,737 patent/US6953854B2/en not_active Expired - Fee Related
-
2005
- 2005-07-14 AU AU2005203071A patent/AU2005203071B2/en not_active Ceased
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2011000437A1 (en) | Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof | |
| CN203777119U (zh) | 跟腱延长术后康复支具 | |
| DE60044152D1 (de) | Bupropion Metaboliten zur Behandlung von Angstzuständen | |
| NZ526868A (en) | Substituted alkylamine derivatives and methods of use for treating cancer and angiogenesis related disorders | |
| GT200400098A (es) | Metodo de tratamiento de aterosclerosis, dislipidemias y condiciones relacionadas y composiciones farmaceuticas. | |
| IL186200A (en) | Use of amylin and agonists, analogues and derivatives of amylin for the preparation of a drug for the treatment of psychiatric illness | |
| ECSP024393A (es) | Derivados biciclicos sustituidos para el tratamiento del crecimiento celular normal | |
| PL371428A1 (en) | Substituted indolizine-like compounds and methods of use | |
| MY167602A (en) | Amine derivatives compounds for treating ophthalmic diseases and disorders | |
| JO2505B1 (en) | Pharmacy methods and formulations for obtaining acceptable serum testosterone levels | |
| MXPA05013469A (es) | Derivados de piperazina y metodos de uso. | |
| Sangkaew | Distraction osteogenesis for the treatment of post traumatic complications using a conventional external fixator: a novel technique | |
| CO5370677A1 (es) | Nuevos derivados heterociclicos de carbonil sustituido y su uso como ligantes receptores d3 de dopamina | |
| MXPA03006943A (es) | Derivados de carbonilo sustituidos heterocicliclos y su uso como ligandos para el receptor d3 de la dopamina. | |
| WO2002066469A3 (en) | Novel heterocyclic amide derivatives and their use as dopamine d3 receptor ligands | |
| WO2010011836A3 (en) | Treating various disorders with 7,8-dihydroxyflavone and derivatives thereof | |
| CL2019002601A1 (es) | Derivados pirazol[1,5-a]pirimidina sustituidos con alicíclicos farmacológicamente activos. | |
| PA8519401A1 (es) | Derivados de 3-azabiciclo(3.1.0)hexano utiles en terapia | |
| PE20011140A1 (es) | Proceso para preparar forma i cristalina de cabergolina | |
| PE20011087A1 (es) | Forma ii cristalina de cabergolina | |
| NO20080393L (no) | Halogenerte pyrazolo [1,5-A] pyrimidiner, fremgangsmater, anvendelse som GABA-A reseptorligander, sammensetninger og intermediater | |
| MX2009002906A (es) | Derivados de piridina para el tratamiento de trastornos metabolicos relacionados con la resistencia a insulina o hiperglicemia. | |
| AR033973A1 (es) | Forma vii cristalina de cabergolina, es decir, 1((6-alilergolin-8beta-il)-carbonil)-1-(3-dimetilaminopropil)-3-etilurea, un proceso para producir dicha forma vii, y una composicion farmaceutica que la comprende | |
| WO2014144584A3 (en) | Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions | |
| MXPA03006843A (es) | Derivados heterociclicos novedosos de ureas y su uso como ligandos para receptor d3 de dopamina. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |